scPharmaceuticals Q2 revenue beats expectations

Scpharmaceuticals

07/08/2025 21:31

Overview

scPharmaceuticals Q2 revenue of $16 mln beats analyst expectations, per LSEG data

Net loss of $18 mln missed analyst estimates, per LSEG data

Company launched FUROSCIX for chronic kidney disease, expanding its market reach

Result Drivers

REVENUE GROWTH - Net FUROSCIX revenue increased 99% year-over-year to $16 mln, driven by higher demand and expanded market reach

DOSE INCREASE - Doses shipped to patients rose 117% year-over-year, reflecting strong adoption among prescribers

CKD MARKET EXPANSION - Launch of FUROSCIX in chronic kidney disease market contributed to revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$16.04 mln
$15.40 mln (5 Analysts)
Q2 Net Income
Miss
-$18.02 mln
-$16.80 mln (4 Analysts)
Q2 Income from Operations
Beat
-$14.29 mln
-$15.90 mln (4 Analysts)
Q2 Basic EPS
-$0.34
Q2 Operating Expenses
$30.34 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for scPharmaceuticals Inc is $12.00, about 56.2% above its August 6 closing price of $5.26

Press Release: ID:nGNX24CJrR

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)